HOME >> BIOLOGY >> NEWS
NIH launches 'Health Info Rx Program' on newborn screening and related genetic disorders

After a doctor sees a patient, he or she often prescribes medications. But what if such a doctor also wants to direct a patient to up-to-date, reliable, consumer-friendly information about a genetic condition, or an explanation of the basics of genetic science? Under a new program launched today, practitioners are being encouraged to refer their patients to Genetics Home Reference, a free, patient-friendly Web site of the National Institutes of Health (NIH), at http://ghr.nlm.nih.gov.

Under this program, doctors can request free "Information Rx" pads, which will enable them to write "prescriptions," pointing patients to the Genetics Home Reference site and to the wealth of information it contains. Obstetricians can direct their patients to the site's explanation of newborn screening, so expectant mothers will better understand why this testing will be important for their baby.

Pediatricians and family physicians who see new moms and dads often provide good advice on newborn or child care concerns. If there happens to be a problem detected in a screening, where should this doctor direct the concerned parents for reliable, easy-to-read information at a stressful time? NIH's Genetics Home Reference can be an invaluable resource.

All states screen newborns for certain genetic disorders. These conditions are usually not apparent in the newborn, but can cause physical problems, mental retardation and, in some cases, death.

Micki Gartzke, a patient advocate from Shorewood, Wisconsin, lost her 13-month-old daughter, LeA Marie, to a rare genetic disorder, Krabbe disease, in 1987. "As a parent, of course you want every possible piece of information when you find out your child is sick. The Internet back then was in its infancy --resources were scattered and I did a lot of hunting and pecking to find things that would help us. It's so gratifying to see a resource like Genetics Home R
'"/>

Contact: Robert Mehnert
publicinfo@nlm.nih.gov
301-496-6308
NIH/National Library of Medicine
20-Nov-2006


Page: 1 2 3

Related biology news :

1. Springer launches Theoretical Ecology
2. NCRR launches national network to connect investigators based at minority institutions
3. Scientific American launches innovative new version of magazine
4. University of Arizona launches major scientific research initiative at Biosphere 2
5. Brazils first oncology biotech launches
6. University of Liverpool launches 10 million small animal teaching hospital
7. UCI launches effort to develop patient-specific stem cell lines
8. New network launches to keep UK at forefront of stem cell science
9. Geisinger launches extensive study on obesity and related liver problem
10. Elsevier launches new journal, Marine Genomics
11. NIH neuroscience microarray consortium launches high-throughput genotyping services

Post Your Comments:
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided ...
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation ... largest exhibition for service robots ever held in ... takes place on May 11-13, 2015 at the ... exhibitors for the event include: Acorn Product Development; ... EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya ...
(Date:3/12/2015)... 2015 WHEN:Tuesday, March 17, 2015 at 11:00 ... . SPEAKERS: , Frost & Sullivan Measurement & ... Biometric companies must plan for ... different markets and industries. This is especially true ... Join Frost & Sullivan,s upcoming ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
(Date:3/30/2015)... PMG Research, Benchmark Research, and Miami ... of VaxCorps, a network of highly experienced, geographically ... of vaccine trials in healthy adult, elderly, and ... conducted over 500 phase I-III vaccine clinical trials, ... as well as a vast array of other ...
(Date:3/30/2015)... 30, 2015  NuGene International, Inc. ("NuGene") (OTCQB: ... BioPharma, Inc. has added another internationally recognized researcher ... is an internationally recognized researcher in bio-inspired materials ... at Peking University, China , ... University of North Carolina, Chapel Hill. Following a ...
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... Md. , March 30, 2015  Spherix ... company committed to the fostering and monetization of ... v. VTech,  Case No. 3:13-cv-03494-M and  Spherix v. ... United States District Court for the Northern District ... update regarding Spherix v. Verizon, Case ...
Breaking Biology Technology:PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3
Cached News: